Although methimazole (MMI) and propylthiouracil (PTU) have long been used to treat hyperthyroidism caused by Graves' disease (GD), there is still no clear conclusion about the choice of drug or appropriate initial doses.
D ESPITE METHIMAZOLE (MMI) and propylthiouracil
(PTU) having been used for more than half a century to treat hyperthyroidism caused by Graves' disease (GD), controversy still exists in antithyroid drug (ATD) therapy. For example, according to a survey reported in 1991, MMI was selected as the drug for initial treatment in Japan and Europe, whereas PTU was preferred in the United States (1) . Which is more suitable, MMI or PTU, in terms of drug efficacy or adverse effects? In Japan, treatment with MMI 30 mg daily has been "a standard regimen" for GD for a long time, but some reports have insisted that a smaller dosage such as 15 mg daily of MMI is as effective as the standard of 30 mg (2) (3) (4) . How much should the initial ATD dosage be, a moderate dosage such as 30 mg daily of MMI or a smaller dosage of 15 mg?
The Japan Thyroid Association has been formulating a guideline for the treatment of hyperthyroidism caused by GD, but the data collected on ATD therapy over time were indeterminate on drug selection or suitable starting dosage. Therefore, we undertook this prospective randomized clinical study on initial treatments for thyrotoxic GD to decide the most suitable regimen by comparing the standard treatment of MMI 30 mg/d with PTU 300 mg/d and MMI 15 mg/d in terms of the short-term efficacy and adverse effects.
Patients and Methods Patients
Only patients with untreated hyperthyroidism due to GD were recruited. GD was diagnosed according to Japan Thyroid Association's diagnosis guidelines (http://thyroid.umin.ac.jp/en/frame.html), defined by clinical findings and the determination of serum free T 4 (FT4), free T 3 (FT3), TSH, TSH receptor antibody (TRAb), and 123 I-or 99m Tcuptake. The following conditions excluded patients from the study: age younger than 16 yr old; pregnancy; relapsed patients after subtotal thyroidectomy or radioiodine therapy; previous treatment with ATD; severe complications, such as heart failure; and patients on glucocorticoid steroids or drugs that may influence thyroid functions. A total of 396 patients with untreated GD were initially recruited for the study, with 93 patients excluded from the final analysis of the ATD treatment due to the reasons in Table 1 . The percentage of withdrawal was less in the MMI 15-mg group than for other groups due to the significantly less occurrence of early adverse effects. Finally, 303 patients (134 patients at Ito Hospital, 92 at Kuma Hospital, 62 at Hamamatsu University Hospital and 15 at Sumire Hospital) were evaluated. For the adverse event analysis, 371 patients (excluding 25 dropout patients) were examined.
Patients were scheduled to visit the hospitals at 2, 4, 8, and 12 wk after initiation of their treatment. Adverse effects of the drugs were looked for systematically by careful health interview and clinical examinations. Aspirate aminotransferase (AST), alanine aminotransferase (ALT), ␥ glutamyl transpeptidase, and hematological values were measured for evaluation every visit to the outpatient clinic. Serum FT4 and FT3 with or without TSH were assayed at 4, 8, and 12 wk. When serum FT4 and FT3 were both within normal ranges (FT4, 0.8 -1.6 ng/dl; FT3, 3.1-4.9 pg/ml), the dosages of ATD were lessened as follows: MMI from 30 to 15 mg; from 15 to 10 mg; and PTU from 300 to 150 mg. After that, patients were given suitable doses of ATD to maintain normal thyroid hormone (TH) concentrations. When necessary, ␤-blocker was given concomitantly. The initial dose of ATD was continued without increasing for 12 wk, even if TH did not fall into the normal range. Each of the four hospitals obtained the values for serum FT4 and FT3 within 60 min after taking blood samples at outpatient clinics, and doctors could decide the dose of ATD after checking hormone values.
The number of patients finally analyzed for ATD effectiveness was 98 in the MMI 30-mg, 81 in the PTU 300-mg, and 124 in the MMI 15-mg groups, respectively. The ratio of sex, values for age, and initial TRAb before treatment did not differ between groups (Table 1) . Before ATD treatment, all patients had elevated FT4 levels more than 2 ng/dl.
Methods
Serum FT4, FT3, and TSH were measured with a Roche ECLusys kit (Roche, Basel, Switzerland) in Ito Hospital, Sumire Hospital, and Hamamatsu University Hospital, or Architect kits (Abbott Japan Co., Ltd, Osaka 540-0001 Japan) in Kuma Hospital. Although values for the hormones obtained by these two assay kits differed slightly, the data were combined for the analyses because the difference was small (data not shown). The normal values and measurable ranges are as follows:
FT4 0.8 -1.6 ng/dl (measurable range up to 7 ng/dl), FT3 3.1-4.9 pg/ml (measurable range up to 30 pg/ml). TRAb (normal range 0 -10%) was assayed with TRAb-CT (Cosmic Corporation, Tokyo, Japan).
Statistical analysis
Data were analyzed statistically using the 2 test for independence and comparison of frequencies. When expected values less than 5 are included in the table of the data, Fisher's exact probability test was used instead of the 2 test. For comparison of age and TRAb values among the three groups, ANOVA was used. Calculations were performed using StatView, version 5.0 (SAS Institute Inc., Cary, NC). Statistical significance was defined as P Ͻ 0.05.
Results

Comparisons of the efficiency of the MMI 30 mg/d treatment with that of the PTU 300 mg/d and MMI 15 mg/d treatment
At 4 wk after initial treatment, serum FT4 levels went down less than 1.7 ng/dl in 52.7%, 38.4%, and 36.7% of the patients treated with MMI 30 mg/d, PTU 300 mg/d, and MMI 15 mg/d, respectively. MMI 15 mg/d was significantly less effective than MMI 30 mg/d (P ϭ 0.023). At 8 wk, their ratios were 81.3%, 68.5%, and 70.0%, respectively, and the statistical difference between MMI 30 mg/d with PTU 300 mg/d and MMI 15 mg/d was marginal. At 12 wk, the efficacy was significantly different between them because 96.5% of the patients on MMI 30 mg reached normal FT4, while 78.3% on PTU 300 mg (P Ͻ 0.001) and 86.2% on MMI 15 mg (P ϭ 0.023) (Fig. 1) .
Because the severity of hyperthyroidism varied among the patients, we divided the patients into two groups according to their pretreatment serum FT4 values; group A included patients with initial FT4 less than 7 ng/dl and group B with 7 ng/dl or more. There was no difference in the pretreatment FT4 and FT3 values in group A (data not shown), and almost all patients in group B had FT4 above the measurable range. In group A, no difference was found between the treatments at 4 and 8 wk, but at 12 wk, MMI 30 mg/d achieved normal FT4 in every patient, while PTU 300 mg/d and MMI 15 mg/d induced normal FT4 in 87.5% and 92%, respectively, with a statistically significant difference (Fig. 2, upper) (Fig. 2, lower) . A total of 396 patients with untreated GD were initially recruited for the study, with 93 patients excluded from the final evaluation for short-term efficacy of the ATD treatments due to side effects within 4 wk, not visiting a hospital regularly, or dropout. Finally, 303 patients (134 patients at Ito Hospital, 92 at Kuma Hospital, 62 at Hamamatsu University Hospital, and 15 at Sumire Hospital) were analyzed. For the adverse event analysis, 371 patients excluding 25 dropout patients were examined.
When the efficiency of these ATD regimens was analyzed in terms of achieving normal FT3 levels (Ͻ5 pg/ml), a similar tendency was found, although the difference was less evident (Table 2) . For whole patients, MMI 30 mg/d induced normal FT3 more efficiently than PTU 300 mg/d at 8 wk (75.6% vs. 57.4%, respectively; P ϭ 0.021) and 12 wk (90.0% vs. 62.9%, respectively; P Ͻ 0.001). When the patients in groups A and B were analyzed, there was no difference between the treatments at 4 and 8 wk, but at 12 wk, MMI 30 mg/d was more effective than PTU 300 mg/d and MMI 15 mg/d. The efficiency to achieve normal FT3 level was almost half with PTU 300 mg/d compared with MMI 30 mg/d (66.7 vs. 35.0%, respectively; P ϭ 0.043) in group B. No relation was found between the efficacy of ATD to normalize TH and age, sex, initial TRAb values, or goiter size (data not shown). Table 3 summarizes the incidence of adverse effects in the ATD regimen groups. The incidence was surprisingly high in the PTU group, in which more than half the patients (54 of 104) had some adverse effects. PTU was stopped or changed to MMI for 39 patients. In the MMI 30-mg group, adverse effects occurred in 39 of 130 patients (30%), and the drug was stopped or changed for 28 patients. The difference was statistically significant between the PTU group and the MMI 30-mg group. We found a very high incidence of elevation of transaminase values with PTU. The percentage of patients who showed AST and ALT higher than double the upper range of the normal standard was 26.9% on PTU 300 mg/d, compared with only 6.6% on MMI 30 mg/d (P Ͻ 0.001). Skin eruption or urticaria similarly occurred in about 22% in either group, but leukocytopenia (less than 1000/l) was observed in five patients in the PTU group only. One patient treated with MMI 30 mg/d had arthralgia, and the drug was discontinued. Fortunately, no patient experienced serious side effects, such as agranulocytosis.
Comparison of adverse events between MMI 30 mg/d and PTU 300 mg/d or MMI 15 mg/d
On the contrary, MMI 15 mg/d caused significantly fewer adverse events than MMI 30 mg/d. The total incidence in the MMI 15 mg group was about half that of the MMI 30-mg group. Although the frequency of mild hepatotoxicity was similar, skin eruption/urticaria induced by MMI 15 mg was only about one third that of MMI 30 mg.
Discussion
There have been only limited studies that compared the effectiveness of MMI and PTU to treat hyperthyroidism caused by GD. Okamura et al. (5) reported that MMI 30 mg/d normalized more rapidly TH than PTU 300 mg/d. The mean time required to normalize TH was 6.7 Ϯ 4.6 wk by MMI and 16.8 Ϯ 13.7 wk by PTU (P Ͻ 0.05). However, their study was retrospective, and it was unclear whether the patients in each group were truly equivalent (5). In fact, only 17 patients were treated with PTU, one fourth that of MMI. There were four prospective randomized controlled trials (RCTs) to compare MMI and PTU (6 -9) , and the results of these studies indicated the tendency that MMI is somewhat more effective. However, the conclusion should be cautious because of the small number of patients in each group (6, 7, 9) . In addition, in one study, both ATDs were given in a single daily usage (8) . Because the half-life of PTU is much shorter than that of MMI and a single daily dose regimen is known to be less effective than a divided dose regimen for PTU administra- there were some limitations. In the RCT by Shiroozu et al. (2) , a significant number of patients were considered to be mild because 20 -35% of the patients had TRAb values less than 15%. In addition, the dropout ratio was as high as 20%, and a retrospective control group was included. In the study by Mashio et al. (3, 4) , no information was given about the ratio of dropout patients. Both studies did not pay any attention to the baseline severity of the disease before treatment. Analysis based on the baseline severity of hyperthyroidism is important because it is quite conceivable that a small amount of ATD may be suitable for mild GD but unsuitable for very severe hyperthyroid patients. There has been only one study reporting such an analysis (12) , which observed that 20 mg/d carbimazole, a precursor of MMI, was too low for severe Graves' patients (initial T 4 Ͼ 20 g/dl) but adequate for less severely hyperthyroid patients. The data are interesting and suggestive, but the number of patients in each group was very small (just seven to nine subjects). Our RCT showed that the MMI 30 mg/d treatment is clearly superior in the effectiveness to achieve normal TH than PTU 300 mg/d and MMI 15 mg/d, especially for patients with severe hyperthyroidism.
Regarding adverse effects, minor ones occurred in as high as 52% of patients treated with PTU 300 mg/d, while 30% and 13.9% with MMI 30 mg/d and MMI 15 mg/d, respectively, in our study. The frequency of minor side effects was reported not to differ between MMI and PTU (13) , but this is the first RCT that demonstrated the significantly higher frequency of adverse effects in PTU than MMI. Notably PTU induced mild liver damages four times higher than MMI 30 mg/d. Liaw et al. (14) reported that although PTU commonly induces subclinical and asymptomatic liver injury, liver damage is usually transient, and PTU may be continued with caution. However, we stopped the initial medication when AST or ALT elevated more than double the normal level because of the risk of PTU-induced severe hepatotoxicity. Williams et al. (15) collected two of their own and 28 cases in the literature of PTU-induced severe hepatic toxicity and reported that seven patients died. MMI 15 mg/d is evidently advantageous over MMI 30 mg/d, with a total incidence less 
